120 related articles for article (PubMed ID: 12606756)
1. Molecular modeling of interactions of dihydropyridines and phenylalkylamines with the inner pore of the L-type Ca2+ channel.
Lipkind GM; Fozzard HA
Mol Pharmacol; 2003 Mar; 63(3):499-511. PubMed ID: 12606756
[TBL] [Abstract][Full Text] [Related]
2. Homology model of dihydropyridine receptor: implications for L-type Ca(2+) channel modulation by agonists and antagonists.
Zhorov BS; Folkman EV; Ananthanarayanan VS
Arch Biochem Biophys; 2001 Sep; 393(1):22-41. PubMed ID: 11516158
[TBL] [Abstract][Full Text] [Related]
3. Structural model for dihydropyridine binding to L-type calcium channels.
Tikhonov DB; Zhorov BS
J Biol Chem; 2009 Jul; 284(28):19006-17. PubMed ID: 19416978
[TBL] [Abstract][Full Text] [Related]
4. Key roles of Phe1112 and Ser1115 in the pore-forming IIIS5-S6 linker of L-type Ca2+ channel alpha1C subunit (CaV 1.2) in binding of dihydropyridines and action of Ca2+ channel agonists.
Yamaguchi S; Zhorov BS; Yoshioka K; Nagao T; Ichijo H; Adachi-Akahane S
Mol Pharmacol; 2003 Aug; 64(2):235-48. PubMed ID: 12869628
[TBL] [Abstract][Full Text] [Related]
5. Structural model for phenylalkylamine binding to L-type calcium channels.
Cheng RCK; Tikhonov DB; Zhorov BS
J Biol Chem; 2009 Oct; 284(41):28332-28342. PubMed ID: 19700404
[TBL] [Abstract][Full Text] [Related]
6. Conserved Ca2+-antagonist-binding properties and putative folding structure of a recombinant high-affinity dihydropyridine-binding domain.
Huber I; Wappl E; Herzog A; Mitterdorfer J; Glossmann H; Langer T; Striessnig J
Biochem J; 2000 May; 347 Pt 3(Pt 3):829-36. PubMed ID: 10769189
[TBL] [Abstract][Full Text] [Related]
7. Molecular determinants of diltiazem block in domains IIIS6 and IVS6 of L-type Ca(2+) channels.
Hockerman GH; Dilmac N; Scheuer T; Catterall WA
Mol Pharmacol; 2000 Dec; 58(6):1264-70. PubMed ID: 11093762
[TBL] [Abstract][Full Text] [Related]
8. Molecular studies on the voltage dependence of dihydropyridine action on L-type Ca2+ channels. Critical involvement of tyrosine residues in motif IIIS6 and IVS6.
Bodi I; Yamaguchi H; Hara M; He M; Schwartz A; Varadi G
J Biol Chem; 1997 Oct; 272(40):24952-60. PubMed ID: 9312099
[TBL] [Abstract][Full Text] [Related]
9. Molecular determinants of drug binding and action on L-type calcium channels.
Hockerman GH; Peterson BZ; Johnson BD; Catterall WA
Annu Rev Pharmacol Toxicol; 1997; 37():361-96. PubMed ID: 9131258
[TBL] [Abstract][Full Text] [Related]
10. Dihydropyridine receptor of L-type Ca2+ channels: identification of binding domains for [3H](+)-PN200-110 and [3H]azidopine within the alpha 1 subunit.
Striessnig J; Murphy BJ; Catterall WA
Proc Natl Acad Sci U S A; 1991 Dec; 88(23):10769-73. PubMed ID: 1660150
[TBL] [Abstract][Full Text] [Related]
11. Molecular determinants of high affinity dihydropyridine binding in L-type calcium channels.
Peterson BZ; Tanada TN; Catterall WA
J Biol Chem; 1996 Mar; 271(10):5293-6. PubMed ID: 8621376
[TBL] [Abstract][Full Text] [Related]
12. Allosteric interactions required for high-affinity binding of dihydropyridine antagonists to Ca(V)1.1 Channels are modulated by calcium in the pore.
Peterson BZ; Catterall WA
Mol Pharmacol; 2006 Aug; 70(2):667-75. PubMed ID: 16675661
[TBL] [Abstract][Full Text] [Related]
13. Construction of a high-affinity receptor site for dihydropyridine agonists and antagonists by single amino acid substitutions in a non-L-type Ca2+ channel.
Hockerman GH; Peterson BZ; Sharp E; Tanada TN; Scheuer T; Catterall WA
Proc Natl Acad Sci U S A; 1997 Dec; 94(26):14906-11. PubMed ID: 9405712
[TBL] [Abstract][Full Text] [Related]
14. Distinct properties of amlodipine and nicardipine block of the voltage-dependent Ca2+ channels Cav1.2 and Cav2.1 and the mutant channels Cav1.2/dihydropyridine insensitive and Cav2.1/dihydropyridine sensitive.
Lin M; Aladejebi O; Hockerman GH
Eur J Pharmacol; 2011 Nov; 670(1):105-13. PubMed ID: 21910984
[TBL] [Abstract][Full Text] [Related]
15. Calcium binding in the pore of L-type calcium channels modulates high affinity dihydropyridine binding.
Peterson BZ; Catterall WA
J Biol Chem; 1995 Aug; 270(31):18201-4. PubMed ID: 7629136
[TBL] [Abstract][Full Text] [Related]
16. A genetic screen for dihydropyridine (DHP)-resistant worms reveals new residues required for DHP-blockage of mammalian calcium channels.
Kwok TC; Hui K; Kostelecki W; Ricker N; Selman G; Feng ZP; Roy PJ
PLoS Genet; 2008 May; 4(5):e1000067. PubMed ID: 18464914
[TBL] [Abstract][Full Text] [Related]
17. Differential sensitivities of CaV1.2 IIS5-S6 mutants to 1,4-dihydropyridine analogs.
Hui K; Kwok TC; Kostelecki W; Leen J; Roy PJ; Feng ZP
Eur J Pharmacol; 2009 Jan; 602(2-3):255-61. PubMed ID: 19068212
[TBL] [Abstract][Full Text] [Related]
18. Modeling of the outer vestibule and selectivity filter of the L-type Ca2+ channel.
Lipkind GM; Fozzard HA
Biochemistry; 2001 Jun; 40(23):6786-94. PubMed ID: 11389592
[TBL] [Abstract][Full Text] [Related]
19. Characterizing the 1,4-dihydropyridines binding interactions in the L-type Ca2+ channel: model construction and docking calculations.
Cosconati S; Marinelli L; Lavecchia A; Novellino E
J Med Chem; 2007 Apr; 50(7):1504-13. PubMed ID: 17335186
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the dihydropyridine receptor site of L-type calcium channels by alanine-scanning mutagenesis.
Peterson BZ; Johnson BD; Hockerman GH; Acheson M; Scheuer T; Catterall WA
J Biol Chem; 1997 Jul; 272(30):18752-8. PubMed ID: 9228048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
